Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REC-4881 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo (Part 1) | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo administered orally and then, following 14-28 days, participants will begin once daily (QD) dosing for another 14 days. |
| REC-4881 4 mg (Part 1) | EXPERIMENTAL | Participants will receive REC-4881 4 milligrams (mg) administered orally and then, following 14-28 days, participants will begin QD dosing for another 14 days. |
| REC-4881 4 mg (Part 2): QD Treatment Regimen | EXPERIMENTAL | Participants will receive REC-4881 4 mg administered orally QD for 12 weeks followed by a 12 week off-treatment period. |
| REC-4881 8 mg (Part 2): QD Treatment Regimen | EXPERIMENTAL | Participants will receive REC-4881 8 mg administered orally QD for 12 weeks followed by a 12 week off-treatment period. |
| REC-4881 4 mg (Part 2): Interval Dosing Treatment Regimen | EXPERIMENTAL | Participants will receive REC-4881 4 mg administered orally in a 7 day on and off schedule for 24 weeks. |
| Name | Type | Description |
|---|---|---|
| REC-4881 | DRUG | REC-4881 capsules |
| Placebo | DRUG | Placebo capsules |
Inclusion Criteria: 1. Male or female and ≥ 18 years of age 2. Have provided written informed consent to participate in the study 3. Diagnosis of phenotypic classical FAP with disease involvement of the duodenum or the residual colon/rectum/pouch as the primary disease site. 4. Genetic diagnosis of...
REC-4881 is an investigational small molecule being developed for Familial Adenomatous Polyposis (FAP), a gastrointestinal condition. It is currently in Phase 1 clinical development and has not been approved by the FDA.
REC-4881 targets MEK, a protein involved in cell signaling. By inhibiting MEK, the drug aims to interfere with pathways that contribute to the growth of polyps in Familial Adenomatous Polyposis.
REC-4881 is being developed by Recursion Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol RXRX.
REC-4881 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The drug has been granted Orphan Drug and Fast Track designations by the FDA.
REC-4881 is being studied in a Phase 1 clinical trial with the identifier NCT05552755. This trial is recruiting participants with Familial Adenomatous Polyposis in the United States and has an estimated enrollment of 67 participants.
REC-4881 is a unique investigational compound developed by Recursion Pharmaceuticals. No alternative names for this drug have been reported.